Thyroid disease and pulmonary arterial hypertension (PAH) in patients treated with prostacyclin

被引：0
|
作者：
Ferris, AM [1 ]
Morse, JH [1 ]
Jacobs, T [1 ]
Rosenzweig, EB [1 ]
Aranoff, GS [1 ]
Barst, RJ [1 ]
机构：
[1] Columbia Univ, New York, NY USA
来源：
CIRCULATION | 2000年 / 102卷 / 18期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
2075
引用
收藏
页码：426 / 427
页数：2
相关论文
共 50 条
  • [21] Similarities between Pulmonary Hypertension (PHT) Complicating Lung Disease and Pulmonary Arterial Hypertension (PAH)
    Higton, A. M.
    Whale, C. I.
    Fernandez, N. A.
    Jary, C. J.
    Lawrence, S.
    Musk, M. T.
    Gabbay, E.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2009, 179
  • [22] Expert Council resolution on pulmonary arterial hypertension (PAH) "Changing the paradigm of treating patients with pulmonary arterial hypertension"
    Chazova, I. E.
    Martynyuk, T. V.
    TERAPEVTICHESKII ARKHIV, 2019, 91 (03) : 114 - 116
  • [23] Effect of riociguat on pulmonary arterial compliance in patients with pulmonary arterial hypertension (PAH) in the RESPITE study
    Hoeper, Marius M.
    Corris, Paul A.
    Ghofrani, Hossein-Ardeschir
    Klinger, James R.
    Langleben, David
    Naeije, Robert
    Simonneau, Gerald
    Jansa, Pavel
    Rosenkranz, Stephan
    Grunig, Ekkehard
    Scelsi, Laura
    Meier, Christian
    Busse, Dennis
    Benza, Raymond L.
    EUROPEAN RESPIRATORY JOURNAL, 2017, 50
  • [24] Effect of Riociguat on Pulmonary Arterial Compliance in Patients With Pulmonary Arterial Hypertension (PAH) in the Respite Study
    Thenappan, Thenappan
    Hoeper, Marius
    Corris, Paul
    Ghofrani, Hossein-Ardeschir
    Klinger, James
    Langleben, David
    Naeije, Robert
    Simonneau, Gerald
    Jansa, Pavel
    Rosenkranz, Stephan
    Grunig, Ekkehard
    Scelsi, Laura
    Meier, Christian
    Busse, Dennis
    Benza, Raymond
    CHEST, 2017, 152 (04) : 1005A - 1006A
  • [25] Prevalence of Pulmonary Arterial Hypertension (PAH) in Patients With Idiopathic Pulmonary Fibrosis (IPF)
    Villar, Adolfo
    Ancochea, Julio
    Xaubet, Antonio
    CHEST, 2014, 145 (03)
  • [26] CHARACTERIZING PATIENTS TREATED WITH MACITENTAN FOR PULMONARY ARTERIAL HYPERTENSION (PAH) IN THE US OPSUMIT USERS REGISTRY (OPUS)
    McLaughlin, V. V.
    Channick, R. M.
    Lickert, C.
    Pruett, J.
    Selej, M.
    Drake, W.
    VALUE IN HEALTH, 2018, 21 : S55 - S55
  • [27] Prognostic Value of the Multicomponent Improvement (MCI) Endpoint in Patients With Pulmonary Arterial Hypertension (PAH) Treated With Sotatercept
    Waxman, A. B.
    Badesch, D. B.
    Gibbs, J. S. R.
    Ghofrani, H. A.
    Gomberg-Maitland, M.
    Humbert, M. J.
    Mclaughlin, V. V.
    Preston, I. R.
    Souza, R.
    Grunig, E.
    Kope, G.
    Meyer, G. Bohns
    Olsson, K. M.
    Rosenkranz, S.
    Zhao, Y.
    Lau, A.
    Cornell, A. G.
    Pena, J.
    Hoeper, M. M.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2024, 209
  • [28] Thyroid Gland in a Patient with Pulmonary Arterial Hypertension Treated with Epoprostenol
    Abughazaleh, S. J.
    Safdar, Z.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2019, 199
  • [29] LONG TERM SURVIVAL AND TRANSPLANT RATES IN PULMONARY ARTERIAL HYPERTENSION PATIENTS TREATED WITH PARENTERAL PROSTACYCLIN THERAPY
    Ghosh, Sudeshna
    Shah, Trushil
    Bartolome, Sonja
    Gordon, Rhoda Annoh
    Chin, Kelly
    CHEST, 2020, 158 (04) : 2262A - 2263A
  • [30] IMPROVED SURVIVAL IN PATIENTS WITH SYSTEMIC SCLEROSIS (SSC)-RELATED PULMONARY ARTERIAL HYPERTENSION (PAH) AND INTERSTITIAL LUNG DISEASE (ILD) TREATED WITH AGGRESSIVE USE OF PAH THERAPY
    Volkmann, E.
    Saggar, R.
    Borazan, N.
    Torres, B.
    Agrawal, H.
    Flora, M.
    Saggar, R.
    Maranian, P.
    Furst, D. E.
    ANNALS OF THE RHEUMATIC DISEASES, 2013, 72 : 508 - 509
12345